KINIKSA PHARMACEUTICALS news, videos and press releases - Page 3
For more news please use our advanced search feature.
KINIKSA PHARMACEUTICALS - More news...
KINIKSA PHARMACEUTICALS - More news...
- Kiniksa Announces New Data from Phase 2 Trial of Mavrilimumab in Giant Cell Arteritis to be Presented at Late-Breaking Abstracts Session of American College of Rheumatology Convergence 2020
- Kiniksa Announces Positive Data from Phase 2 Trial of Mavrilimumab in Giant Cell Arteritis
- Kiniksa Announces Rilonacept Analyst Day Now Tuesday, September 29th
- Kiniksa Announces Upcoming Rilonacept Analyst Day
- Kiniksa Announces U.S. Orphan Drug Designation for Mavrilimumab for the Treatment of Giant Cell Arteritis
- Kiniksa Pharmaceuticals to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
- Kiniksa Presents Data on the Burden of Disease in Patients with Recurrent Pericarditis at the European Society of Cardiology Congress 2020
- Kiniksa Pharmaceuticals to Present at the 2020 Wedbush PacGrow Healthcare Conference
- Kiniksa Reports Second Quarter 2020 Financial Results and Highlights Recent Pipeline and Corporate Activity
- Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Upsized Public Offering
- Kiniksa Pharmaceuticals, Ltd. Announces Proposed Public Offering
- Kiniksa Announces U.S. Orphan Drug Designation for Rilonacept for the Treatment of Pericarditis
- Kiniksa Announces Positive Data from Phase 3 Trial of Rilonacept in Recurrent Pericarditis (RHAPSODY)
- Kiniksa Announces Lancet Rheumatology Publication of Clinical Outcomes with Mavrilimumab in COVID-19
- Kiniksa Provides Timing of Second Half 2020 Clinical Data Readouts
- Kiniksa Announces 28-Day Clinical Outcomes Data from Mavrilimumab Treatment Protocol in Severe COVID-19 Pneumonia and Active U.S. IND for Phase 2/3 Clinical Trial
- Kiniksa Pharmaceuticals to Present at 41st Annual Goldman Sachs Global Healthcare Conference
- Kiniksa Announces Upcoming Presentation on Mavrilimumab in COVID-19 Pneumonia and Hyperinflammation at the European E-Congress of Rheumatology 2020
- Kiniksa Pharmaceuticals, Ltd. Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Public Offering
- Kiniksa Pharmaceuticals, Ltd. Announces Proposed Public Offering
- Kiniksa Reports Data for Mavrilimumab in COVID-19 Pneumonia and Hyperinflammation and for Vixarelimab in Diseases Characterized by Chronic Pruritus
- Kiniksa Reports First Quarter 2020 Financial Results and Highlights Recent Corporate and Pipeline Activity
- Kiniksa Announces Phase 2 Clinical Trial of Vixarelimab (KPL-716) in Prurigo Nodularis Meets Primary Efficacy Endpoint
- Kiniksa Announces Early Evidence of Treatment Response with Mavrilimumab in 6 Patients with Severe COVID-19 Pneumonia and Hyperinflammation
- Kiniksa Highlights Phase 2 Study Data Showing the Corticosteroid-Sparing Effect of Rilonacept in Patients with Recurrent Pericarditis at the American College of Cardiology's 69th Annual Scientific Session
- Kiniksa Reports Fourth Quarter and Full-Year 2019 Financial Results and Highlights Recent Pipeline Activity
- Kiniksa Announces Pipeline Progress and Reiterates 2020 Clinical Data Readouts
- Kite and Kiniksa Pharmaceuticals Announce Clinical Collaboration Evaluating Investigational Combination of Yescarta® and Mavrilimumab in Relapsed or Refractory Large B-Cell Lymphoma
- Kiniksa Pharmaceuticals to Present at 38th Annual J.P. Morgan Healthcare Conference